News Article | May 3, 2017
This report studies the Allergy Test market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Allergy Test market by product type and applications/end industries. The global Allergy Test market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. For more information or any query mail at email@example.com The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Allergy Test. United States plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of XX. Geographically, this report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Allergy Test in these regions, from 2012 to 2022 (forecast), covering United States North America Europe Asia-Pacific South America Middle East and Africa The major players in global and United States Allergy Test market, including Biomérieux , Danaher Corporation , Hitachi Chemical Diagnostics, Inc. , Siemens AG , Thermo Fisher Scientific, Inc. , Hob Biotech Group , Hycor Biomedical , Lincoln Diagnostics, Inc. , Omega Diagnostics Group PLC , Stallergenes Greer. The On the basis of product, the Allergy Test market is primarily split into Assay Kits Instruments (Immunoassay Analyzer, Luminometer) Consumables On the basis on the end users/applications, this report covers Hospital Diagnostic Laboratory Clinic Nursing Home 2 Allergy Test Market Overview 2.1 Allergy Test Product Overview 2.2 Allergy Test Market Segment by Type 2.2.1 Assay Kits 2.2.2 Instruments (Immunoassay Analyzer, Luminometer) 2.2.3 Consumables 2.3 Global Allergy Test Product Segment by Type 2.3.1 Global Allergy Test Sales (K Units) and Growth (%) by Types (2012, 2016 and 2022) 2.3.2 Global Allergy Test Sales (K Units) and Market Share (%) by Types (2012-2017) 2.3.3 Global Allergy Test Revenue (Million USD) and Market Share (%) by Types (2012-2017) 2.3.4 Global Allergy Test Price (USD/Unit) by Type (2012-2017) 2.4 United States Allergy Test Product Segment by Type 2.4.1 United States Allergy Test Sales (K Units) and Growth by Types (2012, 2016 and 2022) 2.4.2 United States Allergy Test Sales (K Units) and Market Share by Types (2012-2017) 2.4.3 United States Allergy Test Revenue (Million USD) and Market Share by Types (2012-2017) 2.4.4 United States Allergy Test Price (USD/Unit) by Type (2012-2017) 3 Allergy Test Application/End Users 3.1 Allergy Test Segment by Application/End Users 3.1.1 Hospital 3.1.2 Diagnostic Laboratory 3.1.3 Clinic 3.1.4 Nursing Home 3.2 Global Allergy Test Product Segment by Application 3.2.1 Global Allergy Test Sales (K Units) and CGAR (%) by Applications (2012, 2016 and 2022) 3.2.2 Global Allergy Test Sales (K Units) and Market Share (%) by Applications (2012-2017) 3.3 United States Allergy Test Product Segment by Application 3.3.1 United States Allergy Test Sales (K Units) and CGAR (%) by Applications (2012, 2016 and 2022) 3.3.2 United States Allergy Test Sales (K Units) and Market Share (%) by Applications (2012-2017) 4 Allergy Test Market Status and Outlook by Regions 4.1 Global Market Status and Outlook by Regions 4.1.1 Global Allergy Test Market Size and CAGR by Regions (2012, 2016 and 2022) 4.1.2 North America 4.1.3 Asia-Pacific 4.1.4 Europe 4.1.5 South America 4.1.6 Middle East and Africa 4.1.7 United States 4.2 Global Allergy Test Sales and Revenue by Regions 4.2.1 Global Allergy Test Sales (K Units) and Market Share (%) by Regions (2012-2017) 4.2.2 Global Allergy Test Revenue (Million USD) and Market Share (%) by Regions (2012-2017) 4.2.3 Global Allergy Test Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 4.2.4 North America Allergy Test Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 4.2.5 Europe Allergy Test Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 4.2.6 Asia-Pacific Allergy Test Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 4.2.7 South America Allergy Test Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017) 4.2.8 Middle East and Africa Allergy Test Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 4.2.9 United States Allergy Test Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017) 5 Global Allergy Test Market Competition by Players/Manufacturers 5.1 Global Allergy Test Sales (K Units) and Market Share by Players (2012-2017) 5.2 Global Allergy Test Revenue (Million USD) and Share by Players (2012-2017) 5.3 Global Allergy Test Average Price (USD/Unit) by Players (2012-2017) 5.4 Players Allergy Test Manufacturing Base Distribution, Sales Area, Product Types 5.5 Allergy Test Market Competitive Situation and Trends 5.5.1 Allergy Test Market Concentration Rate 5.5.2 Global Allergy Test Market Share (%) of Top 3 and Top 5 Players 5.5.3 Mergers & Acquisitions, Expansion For more information or any query mail at firstname.lastname@example.org ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com
News Article | May 11, 2017
"The first quarter of 2017 has seen the full resumption of our business," commented James R Howard-Tripp, GeneNews' Chairman and CEO. "In particular, Q1 was marked by the full resumption of testing activities at IDL, the signing of the second partnership agreement with a U.S. healthcare services group, and the launch of a major new diagnostic test, BreastSentry®, for the early detection of breast cancer. In addition to these highlights, GeneNews continued to market its early cancer diagnostic testing through an aggressive outreach campaign to hospitals, clinically integrated networks, large physician groups and other healthcare providers, which is expected to significantly grow our list of users. Overall, the process to "build-up" the business is going well, and puts us in a strong position for the remainder of 2017." Collection Partnership Agreement with Any Lab Test Now GeneNews announced today that IDL has signed a Collection Partnership Agreement (the "Collection Partnership") with Any Lab Test Now® ("ALTN"), pursuant to which IDL will offer all of its early cancer tests, including ColonSentry®, EarlyCDT®-Lung, PHI and BreastSentry®, as well as supportive tests, to physicians and patients via ALTN's 165 locations spread across the United States. "The agreement with ALTN very significantly expands our reach and, together with our existing clients, will allow us to offer our early cancer diagnostic tests throughout much of the U.S.," said Mr. Howard-Tripp. "During April, we received over 3,000 requests for information, most of which were from physicians and patients asking where they could gain access to our tests. This partnership now allows us to link patients and physicians and give them immediate access to locations across the country where IDL testing can be initiated." GeneNews expects the Collection Partnership activities to officially launch before the end of May. Effective July 1, 2015, GeneNews changed its functional and presentation currency to U.S. dollars given the increasing prevalence of U.S. dollar denominated activities of the Company over time. These first quarter 2017 financial results are presented in U.S. dollars and prior period comparable information is restated to reflect the change in presentation currency. Results are reported in accordance with International Financial Reporting Standards. Total revenue for the three-months ended March 31, 2017 was approximately $0.2 million, compared to $0.1 million for the same period in 2016. For the three-month period ended March 31, 2017, GeneNews reported a consolidated net loss of $1.5 million, or $0.02 loss per common share, as compared with a consolidated net loss of $2.7 million, or $0.05 loss per common share, for the three-month period ended March 31, 2016. The $1.2 million decrease in the loss results from the $1.1 million impairment charge taken in 2016 for goodwill from the acquisition of the remaining 50% of IDL, $0.4 million share of loss in IDL (taken until March 15, 2016 when the Company acquired full interest in IDL), $0.2 million decline in loss from revaluation of warrants, $0.2 million in cost of goods sold related to IDL's operations, $0.1 million increase in recognized revenue, offset by $0.4 million increase in general and administrative costs, $0.2 million increase in cost of goods sold, $0.1 million increase in change in fair value of conversion liabilities and $0.1 million increase in finance costs. The Company had approximately $0.1 million in cash and cash equivalents as at March 31, 2017. "While not yet reflected in the Company' financial results, we fully anticipate that our recognized revenue will begin to grow in the months ahead as the tests being performed at IDL translate into collected revenue," added Howard-Tripp. The Company's financial statements and management's discussion and analysis are available on www.sedar.com. During the first quarter of 2017, under its capital commitment agreement with GEM Global Yield Fund LLC SCS ("GEM") and its convertible notes (the "Notes") financing agreement with Alumina Partners LLC ("Alumina"), GeneNews secured approximately $1.3 million in additional funding, most of which was used to support the full resumption of testing activities at IDL, to fund the cost of goods associated with the resulting increased testing volumes, to support the BreastSentry® commercial launch, and to make meaningful progress in reducing GeneNews' trade payables. In connection with these financing activities, the Company issued 2,730,000 common shares and 1,610,000 warrants to GEM and 3,544,398 common shares to Alumina. "It is important to note that the approximate 6.3 million common shares issued during the first quarter do not directly correlate with the Company's financing activities within only that period," said Mr. Howard-Tripp. "For example, under the agreement with GEM, common shares issued during Q1-2017 reflect drawdowns made in the quarter, as well as some made in Q4-2016. In addition, pursuant to the Alumina agreement, the issuance of common shares is at the discretion of Alumina upon conversion of the Notes, and can therefore reflect conversion of Notes issued at any time in the previous year." GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health out-comes through the early diagnosis of disease. Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively. This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
News Article | May 11, 2017
"Among our recent achievements, we are pleased to have been selected to participate in the Addario Lung Cancer Medical Institute's (ALCMI) landmark 400-patient clinical trial, ALCMI-009, which seeks to demonstrate the utility of liquid biopsy in patients with advanced non-small cell lung cancer (NSCLC). Importantly, clinical results from this trial will be used to create a large, well-controlled, uniformly collected biorepository of patient blood samples for liquid biopsy profiling, response to treatment, and monitoring of disease," he added. "Additionally, we entered into a commercial collaboration for liquid biopsy testing with Oregon Health and Sciences University (OHSU), a leading cancer treatment center. In this multi-phase agreement, OHSU's Knight Diagnostic Laboratory will utilize Biocept testing to aid in patient treatment decisions, participate in the development of enhancements to our liquid biopsy platform, and will play a role in beta testing our molecular pathology partnership model, which we expect to roll out later this year. "One of our 2017 strategic initiatives is to partner with leading cancer treatment centers in the United States, such as OHSU, aimed at increasing the commercial adoption of our proprietary Target Selector™ liquid biopsy platform. In addition to OHSU, we signed a laboratory supply agreement for liquid biopsy testing with a national multi-center cancer treatment institution that is using our services for cancer profiling and therapeutic monitoring – the key areas for growth in liquid biopsy. "We also are capitalizing on the growing awareness of liquid biopsy by adding new sales executives to the team, bringing our field force to 12 representatives and three managers. I am enthusiastic about the high caliber of our new hires, and we believe that we are on track to grow our sales team to 15 to 20 representatives by the end of this year," Mr. Nall concluded. Review of First Quarter 2017 and Recent Accomplishments We accessioned 1,107 billable samples during the first quarter of 2017, a 38% increase from 801 billable samples accessioned during the first quarter of 2016. Total sample accessions, which also include samples from research, assay validations, and other non-billable sources, were 1,246 for the first quarter of 2017, also up 38% from 902 total samples for the first quarter of 2016. Revenues for the first quarter of 2017 of $1.68 million increased from $221,000 reported in the first quarter of 2016. First quarter 2017 revenues included $897,000 in commercial test revenues recognized on a cash basis and $61,000 in development services test revenues. During the first quarter of 2017, we converted from cash-based revenue recognition for our commercial revenues, to accrual-based revenue recognition. As a result, revenues for the three months ended March 31, 2017 included the recognition of $726,000 in commercial accounts receivable, net of reserves taken for third-party health plan and patient payments totaling $420,000, as well as reserves for contractual and payer-specific adjustments. Given the timing of the change to accrual accounting, we recognized a total of nonrecurring revenue of $877,000, which relates to revenue recognized in the first quarter of 2017 for commercial tests completed during 2016. Under this method of reporting, we believe that our revenues in future quarters will more accurately align with billable test volumes and operating expenses for the corresponding quarters. Cost of revenues for the first quarter of 2017 of $2.1 million compared with $1.5 million for the first quarter of 2016, with the increase primarily attributable to higher commercial test volumes. As test volumes continue to increase, we expect to leverage our fixed and semi-variable costs, reducing costs per patient sample and improving margins. Research and development expenses for the first quarter of 2017 of $757,000 increased slightly from $728,000 for the prior-year period, due to greater consumption of materials and higher costs associated with research and development activities. General and administrative expenses for the first quarter of 2017 were $1.9 million compared with $1.5 million for the first quarter of 2016, primarily due to higher personnel costs associated with the expansion of our in-house billing and investor relation functions, as well as higher consulting and third-party service provider fees associated with increased commercial activities. Sales and marketing expenses for the first quarters of 2017 and 2016 were unchanged at $1.3 million, notwithstanding higher accession volumes in the first quarter of 2017. The net loss for the first quarter of 2017 was $4.4 million, or 21 cents per share. This compares to a net loss for the first quarter of 2016 of $4.9 million, or 74 cents per share. Cash and cash equivalents were $14.0 million as of March 31, 2017, compared with $4.6 million as of December 31, 2016. On March 31, 2017, we completed an equity offering raising gross proceeds of $9.3 million. Additionally, we benefitted from $5.3 million in cash proceeds from the exercise of warrants in the first quarter of 2017. Biocept will hold a conference call today at 4:30 pm Eastern time to discuss these results and answer questions. The conference call can be accessed by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers. A live webcast of the conference call will be available on the investor relations page of the company's website at http://ir.biocept.com/events.cfm. A replay of the webcast will be available for 90 days. A replay of the call will be available for 48 hours following the conclusion of the call and can be accessed by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers or (412) 317-0088 for other international callers. Please use event passcode 10101325. Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com. This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to provide physicians with clinically actionable information to improve the outcomes of cancer patients, our ability to roll out our molecular pathology partnership model, our ability to increase the commercial adoption of our proprietary Target Selector™ liquid biopsy platform, our ability to grow our sales team, and our ability to make investments to accelerate our growth, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at www.sec.gov. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-reports-first-quarter-2017-financial-results-300456420.html
Mogarekar M.R.,Srtr Government Medical College |
Kulkarni S.K.,Diagnostic Laboratory
Archives of Medical Research | Year: 2015
Background and Aims: Atherosclerosis, the root cause of cardiovascular disease (CVD), has a number of risk factors-some modifiable and some not. CVD increases in women particularly during the postmenopausal period. Small dense low-density lipoprotein (sdLDL), a subclass of LDL, is an important determinant of atherosclerosis in postmenopausal women. Paraoxonase1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme that prevents oxidative modifications in LDL and HDL. With this background, we studied the sdLDL-C, PON1 and lipid profile in postmenopausal women to compare between quality and quantity of LDL. Methods: We studied 80 pre- and postmenopausal women (40/group). The following parameters were studied: lipid profile, sdLDL-C and PON1 levels. With proper statistical tools the correlation between these parameters was studied. Results: Postmenopausal women, in comparison with premenopausal women, have significantly increased levels of serum triglycerides and sdLDL-C and very-low-density lipoprotein cholesterol (VLDL-C) and significantly decreased levels of HDL-C and PON1. PON1 activity was negatively correlated with age, TC, TG, LDL-C and sdLDL-C (r = -0.574, -0.119, -0.226, -0.473 and -0.455, respectively) and positively correlated with HDL-C (r = 0.368), whereas sdLDL-C was positively correlated with age, TC, TG, LDL-C (r = 0.633, 0.485, 0.561 and 0.705, respectively) and negatively with HDL-C (r = -0.235). Stepwise multiple regression analysis demonstrated HDL-C and menopausal status as the best determinant for PON1 (R2 = 0.320, p < 0.05) and menopausal status, LDL-C, TG, and TC were the best determinants for sdLDL-C (R2 = 0.606, p < 0.05). Conclusion: The results of the present study suggest quality, i.e., sdLDL-C, is more important than only LDL-C levels. Similarly, decrease in PON1 and increase in sdLDL-C go hand in hand. This shows that antioxidant capacity is compromised with a qualitative downfall in lipoproteins in postmenopausal women. © 2015 IMSS.
News Article | November 17, 2016
According to a new market research report "Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software, Services), Technique (ELISA, Rapid Test), Application (Infectious Diseases, Endocrinology, Oncology), End User (Clinical Labs, Hospitals) - Global Forecast to 2021" published by MarketsandMarkets, the global market is expected to reach USD 25.45 Billion by 2021 from USD 17.16 Billion in 2016, at a CAGR of 8.2% from 2016 to 2021. Browse 139 market data Tables and 44 Figures spread through 204 Pages and in-depth TOC on "Immunoassay Market" Early buyers will receive 10% customization on this report. This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Immunoassay Market along with the estimates and forecasts of the revenue and market share analysis. The major factors driving the growth of this market are raising incidences of chronic diseases, extensive use of immunoassays in oncology, technological advancements, and cost-effectiveness & rapid analysis of immunoassays. This report segments the Immunoassay Market on the basis of product & service, technology, application, end user, and region. Based on product & service, the Immunoassay Market is segmented into reagents & kits, analyzers, and software & services. The reagents & kits segment is further segmented into ELISA reagents, rapid test reagents, western blot reagents, ELISPOT reagents, RIA reagents, and PCR reagents. The analyzers segment is further categorized into purchase mode and type. By purchase mode, the analyzers segment is segmented into reagent rental purchase and outright purchase and by type; these are divided into open-end systems and closed-ended systems. In 2016, the reagents & kits segment is expected to dominate the global Immunoassay Market. Factors driving this segment include rising number of immunoassay tests due to the increase in aging population, rising prevalence of chronic and infectious diseases, and increased variety of reagents and analytical techniques. Based on technology, the Immunoassay Market is segmented into ELISA, rapid tests, western blot tests, ELISPOT, RIA, and PCR. ELISA is further segmented into platform and generation. On the basis of platform, the ELISA market is divided into chemiluminescence immunoassays (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassays (CI). On the basis of generation, the ELISA market is further divided into first generation, second generation, third generation, and fourth generation and above. The ELISA segment is expected to account for the largest share of the market, owing to expanding use of immunoassay tests in cancer, point-of-care in vitro diagnostics, infectious disease testing, and therapeutic drug level monitoring. On the basis of application, the Immunoassay Market is segmented into infectious diseases, endocrinology, bone and mineral disorders, oncology, cardiology, hematology and blood screening, autoimmune diseases, toxicology, neonatal screening, and other applications. The infectious diseases segment is expected to account the largest market share in 2016. On the basis of end user, the Immunoassay Market is segmented into hospitals, clinical laboratories, blood banks, research & academic laboratories, pharmaceutical companies, CROs, biotechnology companies, and other end users. The hospitals segment is expected to account for the largest share of the global Immunoassay Market in 2016. Major factors driving the growth of this market are the rising prevalence of chronic diseases and increasing healthcare infrastructure. On the basis of region, the Immunoassay Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as technological advancement in the immunoassay products and rising incidence of chronic diseases. Key players in the Immunoassay Market include F. Hoffmann-La Roche Ltd. (Switzerland), Siemens AG (Germany), Abbott Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), and bioMérieux SA (France). Allergy Diagnostics Market by Product (Assay Kits, Instruments (Immunoassay Analyzer, Luminometer), Consumables, Services), Allergen (Food, Inhaled, Drug), Tests (In Vivo, In Vitro), End User (Hospital, Diagnostic Laboratory) - Forecast to 2021 In Vitro Diagnostics (IVD) Quality Controls Market by Application (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology) Source (Serum, Blood, Plasma Based Controls) Type (Instrument Specific & Third Party Controls) - Forecast to 2020 MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Contact: Mr. Rohan MarketsandMarkets 701 Pike Street Suite 2175, Seattle, WA 98101, United States 1-888-600-6441 Email: email@example.com Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
News Article | November 30, 2016
Sarasota, FL, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Zion Research has published a new report titled “Hba1c Testing Device Market by Device Type (Handheld Device and Bench-top Device) and by Technology Type (Ion-exchange HPLC, Enzymatic Assay, Affinity Binding Chromatography, Turbidimetric Inhibition Immunoassay and Other) for Hospitals, Homecare, Diagnostic Laboratory and Research Institutions - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global HbA1c testing device market accounted for around USD 1.20 billion in 2015 and is expected to reach approximately USD 2.20 billion by 2021, growing at a CAGR of around 11 % between 2016 and 2021. Hemoglobin is the red protein molecule responsible for carrying oxygen from lung to the body’s organ and tissues. Glucose molecule sticks to the N-terminal amino acid of the hemoglobin molecule by nonenzymatic attachment to form a hemoglobin A1c or HbA1c, also called as glycosylated hemoglobin molecule. Diabetes mellitus is a common form of diabetes, caused by pancreatic insulin deficiency, which affects metabolization of starch and sugar. HbA1c level reflects the average glucose concentration over the previous period and provides a much better indication of body glucose control than urinary and blood glucose determinations. Browse through 18 Market Tables and 24 Figures spread over 110 Pages and in-depth TOC on “Global Hba1c Testing Device Market: By Type, Technology, Devices, Size, Growth, Trends, Industry Segment and Forecast 2015-2021”. The growth of HbA1c testing device market is propelled by increasing number of diabetes population. Geriatric and obese populations are more prone to diabetes mellitus. Globally, USD 673 billion healthcare expenditure is spent on diabetes management which is 12% of total healthcare expenditure. In 2015, around 5.0 million deaths are due to diabetes. Moreover, emerging technologies for diabetes management and increasing awareness of diabetes preventive care are projected to fuel the growth of HbA1c testing device market. In addition, increasing doctor’s prescription pattern for HbA1c testing is a key factor for generating more demand for the HbA1c testing device. On another hand, the high cost of device and limitation of results of the certain population like pregnant, elderly and non-Hispanic black could be a roadblock in the market. Nonetheless, untapped market and increasing demand for medical tourism in emerging markets are likely to open new opportunities in the forecast period. Based on the device type, the market of the HbA1c testing device has been classified into the handheld device and bench-top device. Bench-top HbA1c testing device is widely used in the diagnostic laboratory due to minimal handling and fastest & accurate results. Bench-top HbA1c testing device segment has acquired the largest market share of more than 65% in 2015 compared to the handheld device and in forecast period handheld HbA1c testing device is projected to grow at the healthy rate. Browse the full "Hba1c Testing Device Market by Device Type (Handheld Device and Bench-top Device) and by Technology Type (Ion-exchange HPLC, Enzymatic Assay, Affinity Binding Chromatography, Turbidimetric Inhibition Immunoassay and Other) for Hospitals, Homecare, Diagnostic laboratory and Research Institutions - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021" report at https://www.zionmarketresearch.com/report/hba1c-testing-device-market Based on the technology the market of the HbA1c testing device has been segmented as ion-exchange HPLC, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay and other. With more than 30% revenue contribution, affinity binding chromatography segment was leading the HbA1c testing device market in 2015 due to increasing investment by the manufacturer in the medical device. HbA1c testing device market is segmented on the basis of end user into hospitals, home care, diagnostic laboratory and research institution. Diagnostic laboratory segment dominated the market followed by home care segment and it is expected to grow at the highest rate in the forecast period. With increasing home care service and demand for homecare HbA1c testing device, homecare segment will exhibit significant growth in the forecast period. Around 44 million people are diabetic and diabetes is one of the leading causes of deaths in North America. This indicates that the demand for the HbA1c testing device is very high and it results in rising healthcare expenditure on diabetes, thus North America was a leading segment in HbA1c testing device market in 2015. North America HbA1c testing device market is expected to show noticeable growth with emerging technologies in the forecast period. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/hba1c-testing-device-market In Europe, more than 59 million people are diabetic and it is continuously increasing resulting in increased disability and enormous healthcare expenditure thus in forecast period, Europe HbA1c testing device market is expected to show significant growth. Asia-Pacific is at the peak of the epidemic of diabetes and this is due to rapid urbanization & industrialization and changes in lifestyle factors. More than 60% of the people with diabetes live in Asia pacific. The effect of chronic diseases in adult life and the resulting epigenetic changes are also responsible for increased risk of diabetes mellitus. China is expected to show the fastest expansion over the forecast period. This will be propelled by an increase in the diabetic population due to urbanization and by expected technology launches. Latin America and the Middle East & Africa HbA1c testing device market is also expected to generate new opportunities in the forecast period. Brazil HbA1c testing device market dominated the Latin America and it is predicted to grow at the noticeable rate in the forecast period. Key operating players in HbA1c testing device market are like Transasia Biomedicals ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare and Trinity Biotech plc. The report segment of global Hba1c Testing Device Market as follows: Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
News Article | November 23, 2016
According to Stratistics MRC, the Global Tuberculosis Diagnostics market is accounted for $2.12 billion in 2015 and is expected to reach $3.12 billion by 2022 growing at a CAGR of 5.6% from 2015 to 2022. Increasing cases of tuberculosis is one of the major factors responsible for high market growth. Furthermore, rising government initiatives, growing requirement of POC in healthcare and increasing geriatric population are some factors that are positively affecting the market. However, lack of awareness among the patients is hindering the market. Detection of Drug Resistance segment is anticipated to grow at a steady growth rate and exploitation of antibiotics contribute to the high prevalence of drug resistance. Asia Pacific is expected to witness a lucrative growth over the forecast period attributed to rapid proliferation of this disease across the region. Some of the key players in this market include Hologic Corporation, Cepheid Inc., Siemens AG, Becton, Dickinson and Company, Abbott Laboratories, Hain Lifesciences GmBH, BioMérieux SA, F.Hoffmann-La Roche AG., Alere, Inc., Sanofi, QIAGEN and Thermo Fisher Scientific, Inc. Test Types Covered: • Detection of Drug Resistance • Detection of Latent Infection • Nucleic Acid Testing • Radiographic Methods • Cytokine Detection Assay • Phage Assay • Diagnostic Laboratory Methods • Other Methods Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements
Abdel-Hamid N.M.,Minia University |
Abdel-Hamid N.M.,Diagnostic Laboratory |
Morsy M.A.,Minia University
Journal of Membrane Biology | Year: 2010
Five fluorouracil (5-FU) is extensively used in the treatment of hepatocellular carcinoma (HCC). It is well documented that 5-FU and its metabolites inhibit DNA synthesis through inhibition of thymidylate synthetase. Little is known about additional pathways for 5-FU in managing HCC. The present experiment was mainly designed to study possible biochemical pathways that can be added to 5-FU's mechanisms of action. Four groups of rats constituted a control group (given saline only), a trichloroacetic acid group (TCA, 0.5 g/kg/day for 5 days, orally), a 5-FU-positive group (75 mg/kg body weight, intraperitoneally, once weekly for 3 weeks) and a TCA-treated with 5-FU group (24 h from last TCA dose). We executed both biochemical-serum alpha-fetoprotein (AFP), liver tissue contents of total glycosaminoglycan (TGAGs), collagen (represented as hydroxyproline), total sialic acid (TSA), free glucosamine (FGA) and proteolytic enzyme activity (as pepsin and free cathepsin-D-and histological examinations of the liver tissue. The results revealed histological changes such as central vein congestion and irregularly shaped, substantially enlarged, vesiculated and binucleated hepatocytes. The nuclei were mostly polymorphic and hyperchromatic, and several vacuolation was noticed in the cytoplasm encircling the nucleus with masses of acidophilic material. 5-FU greatly corrected these changes, except that some necrotic and cytotoxic effects of 5-FU were still shown. AFP was significantly elevated in TCA-intoxicated, but reversed in 5-FU-treated, groups. Increased proteolytic activity by TCA was reversed by 5-FU, which also restored TGAG contents to normal; but both TCA and 5-FU depleted collagen content. TCA significantly elevated FGA but depressed TSA; this action was reversed by 5-FU treatment. In conclusion, it is possible that proteolytic activity, expressed as upregulated pepsin and free cathepsin-D activities, is increased in HCC. This is accompanied by extracellular matrix macromolecular disturbance, manifested as decreased TGAGs, collagen and TSA, with marked increase in FGA liver tissue content. The elevated FGA with depressed TSA content of liver tissue may be attributed to a cancer-hampered N-acetylation of FGA into SA. 5-FU administration markedly depressed hepatic tissue proteolysis, possibly reactivated N-acetylation of FGA into SA and elevated TGAGs without stopping tissue fibrosis as collagen was not affected. This study explores additional pathways for the mechanism of action of 5-FU, through conservation of extracellular matrix composition in situ, inhibiting invasion and metastasis in addition to its DNA-disturbing pathway. © 2010 Springer Science+Business Media, LLC.
News Article | December 28, 2016
Wildlife officials in Pennsylvania have identified a common yet highly poisonous shrub as the one that killed a family of bears in a church parking lot earlier this month. Officers from the West Wyoming Police Department received reports of a dead bear cub found at a local parking lot on Dec. 6. When they arrived at the scene, they found four dead bears instead of just one, all of which showed no apparent signs of trauma. The police department said that it considered the death of the bears as suspicious at the time. To find out what could have killed the animals, wildlife officials sent two of the dead bears to the Animal Diagnostic Laboratory at Pennsylvania State University for testing. Following the laboratory tests, officials discovered that the animals were killed not by human interference but by ingesting a poisonous shrub known as an English Yew. The four bears — a bear sow and her three cubs — could have eaten leaves and seeds of the plant, which is known to be very poisonous to humans and animals alike. According to the Pennsylvania Game Commission (PGC), the English Yew (Taxus baccata) is a species of conifer native to Africa, Europe, and southwest Asia. While the plant can grow up to 30 feet in height, it is often pruned into various sizes and configurations. In eastern North America, the English Yew can be found in urban environments, mostly used as an ornamental shrub in gardens. The plant's relatively long life and ability to grow on different soil types make it an ideal choice for topiaries or hedges. The PGC, however, warned that all species of the plant have an alkaloid compound known as taxine, which has been proven to be fatal if ingested. Animals that have single-chambered stomachs are particularly susceptible to the toxin's effects. The game commission believes that the bear sow and her cubs may have been attracted to the yew just when the plant reached its highest toxin levels and no other food sources were available to them at the time. Mark Ternent, a bear biologist for the PGC, explained that black bears often feed the most when they are about to go into hibernation to build their body fat. This would allow them to last all through the winter. It is likely that the bear sow and her cubs were about to enter hibernation, which is why they went out to forage for food. While wildlife officials have encountered bears that have died from unusual causes before, the PGC said this could be the first involving the poisonous shrub. "This unfortunate occurrence was extremely rare and one we hope will not be repeated," Ternent said. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.
News Article | December 22, 2016
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Medical and Diagnostic Laboratory Services Global Market Report 2017" report to their offering. The medical and diagnostic laboratory services market comprises establishments primarily engaged in the detection and prevention of disease. Medical and diagnostic laboratories perform tests on clinical specimens in order to gain insights and information on patients' health conditions. Where is the largest and fastest growing market for medical and diagnostic laboratory services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The medical and diagnostic laboratory services global market report answers all these questions and many more. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider healthcare services market, and compares it with other markets. For more information about this report visit http://www.researchandmarkets.com/research/2qh9g2/medical_and